Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Eribulin

4 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Treatment

VICCBRE1599

04/11/2016

A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician's Choice for Metastatic Triple Negative Breast Cancer (mTNBC) - (KEYNOTE-119)

Treatment

VICCBRE1462

03/08/2016

A Phase I Dose Escalation Study of POL6326 with Eribulin in Patients with Relapsed Metastatic Breast Cancer

Treatment

VICCBRE1246

03/13/2015

Enhancing Efficacy of Chemotherapy in Triple-Negative/Basal-Like Breast Cancers by Targeting Macrophages: A Phase Ib/II Study of PLX3397 and Eribulin in Patients with Metastatic Breast Cancer

Treatment

VICCBRE1391

04/24/2014

A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib versus Physician's Choice in Previously-Treated, HER2-Negative, Germline BRCA Mutation-Positive Breast Cancer Patients